
    
      The main objective of this randomized phase II comparative study is to evaluate the
      Progression Free survival (PFS) and the safety as co-primary objective of two different
      schedule of administrations of 177lu-dotatate: intensive (every 5 weeks) vs no intensive
      (every 8-10 weeks) The secondary objectives are DCR, the late toxicity, OS and dosimetry.
      Patients with any tumor histotype documented as sst2-positive in pre-study period will be
      enrolled in the study.

      The study will include a total of 618 planned patients. They will be randomly assigned to
      receive 5 cycles of PRRT at intervals of 5 or 8-10 weeks between cycles.
    
  